In a recent development, Barclays has initiated coverage on Repligen (RGEN, Financial), a prominent player in the biotechnology sector. The coverage, led by analyst Luke Sergott, marks a significant move as the firm sets an "Overweight" rating for Repligen.
Barclays has announced a price target of $150.00 USD for RGEN, indicating a positive outlook for the company's future performance. This announcement comes as part of Barclays' efforts to provide investors with insights into strategic opportunities within the biotechnology market.
Repligen (RGEN, Financial) continues to capture the attention of market analysts, and the "Overweight" rating suggests a recommendation for investors to consider increasing their positions in the stock. The price target set by Barclays reflects their confidence in RGEN's growth potential and market position.
This initial coverage by Barclays on Repligen (RGEN, Financial) is a significant indicator of the company's robust prospects and the potential for future gains, making it a noteworthy mention within the investment community.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 15 analysts, the average target price for Repligen Corp (RGEN, Financial) is $183.60 with a high estimate of $220.00 and a low estimate of $140.00. The average target implies an upside of 52.86% from the current price of $120.11. More detailed estimate data can be found on the Repligen Corp (RGEN) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Repligen Corp's (RGEN, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Repligen Corp (RGEN, Financial) in one year is $176.46, suggesting a upside of 46.92% from the current price of $120.11. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Repligen Corp (RGEN) Summary page.
